Bajaj Healthcare reported a profit of ₹13.89 crore in Q1 FY27, a significant turnaround from the previous quarter's loss. Revenue grew to ₹165.63 crore. The company is awaiting NCLT approval for the Genrx acquisition.
Bajaj Healthcare Sees Turnaround in Q1 FY27
₹13.89 crore Profit after Tax; ₹165.63 crore Revenue from Operations.
Reader Takeaway: Profitability restored with revenue growth; Genrx acquisition faces regulatory hurdle.
What just happened
Bajaj Healthcare Limited reported a profit after tax of ₹13.89 crore for the first quarter of fiscal year 2027 (Q1 FY27). This marks a significant recovery from a loss of ₹19.41 crore in the preceding quarter (Q4 FY26). Revenue from operations for Q1 FY27 stood at ₹165.63 crore, an increase from ₹153.06 crore in Q4 FY26.
Why this matters
The company's return to profitability and consistent revenue growth indicate a positive operational trend. This financial recovery is crucial for investor confidence. However, the pending NCLT approval for the Genrx Pharmaceuticals acquisition introduces an element of uncertainty regarding integration and future consolidation.
The backstory
Bajaj Healthcare had previously raised ₹204.97 crore through a preferential allotment. As of June 30, 2026, ₹193.24 crore of these funds have been utilized, with the remaining ₹11.73 crore designated for capital expenditure. The company has also faced past challenges with income reversals linked to geopolitical instability in the Middle East impacting customer payments.
What changes now
With the positive Q1 FY27 results, Bajaj Healthcare is demonstrating improved financial performance. The board has also approved the continuation of Mr. Gopalakrishnan Kesavan's term as a Non-Executive Independent Director, subject to shareholder approval, extending his tenure until August 2030. The key immediate change investors will watch is the progress on the Genrx acquisition.
Risks to watch
The primary risk highlighted is the delay in obtaining NCLT approval for the acquisition of Genrx Pharmaceuticals Private Limited. This regulatory hold-up impacts the expected consolidation of Genrx. Additionally, historical concerns regarding geopolitical instability affecting customer payments in the Middle East remain a monitoring point.
Peer comparison
(No direct peer comparison data available in the filing.)
Context metrics (time-bound)
- Fundraising Utilization: As of June 30, 2026, ₹193.24 crore of the ₹204.97 crore raised via preferential allotment has been utilized.
- Unutilized Funds: ₹11.73 crore remains unutilized, earmarked for capital expenditure.
- Genrx Acquisition Cost: ₹10.85 crore was the acquisition cost for Genrx Pharmaceuticals.
What to track next
Investors should closely monitor the progress of the NCLT approval for the Genrx Pharmaceuticals acquisition. Tracking the company's ability to sustain profitability and revenue growth in subsequent quarters, while managing potential regional economic and geopolitical risks, will be key.